These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1736805)

  • 21. [MSA--a new sensitive tumor marker in breast carcinoma].
    Zahm DM; Greinke C; Nöschel H
    Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
    Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
    Barak V; Carlin D; Sulkes A; Treves A; Biran S
    Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
    J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
    Cheung KL; Robertson FR
    Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
    Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of CA15.3 as a serum tumour marker in breast carcinoma.
    Duncan JL; Price A; Rogers K
    Eur J Surg Oncol; 1991 Feb; 17(1):16-9. PubMed ID: 1995353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
    Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R
    Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
    Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CA15-3 tumor marker in early detection of breast cancer].
    Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
    Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
    Tomlinson IP; Whyman A; Barrett JA; Kremer JK
    Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer?
    Velaiutham S; Taib NA; Ng KL; Yoong BK; Yip CH
    Asian Pac J Cancer Prev; 2008; 9(3):445-8. PubMed ID: 18990019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
    Hayes DF; Zurawski VR; Kufe DW
    J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum bone sialoprotein levels and bone metastases.
    Uccello M; Malaguarnera G; Vacante M; Motta M
    J Cancer Res Ther; 2011; 7(2):115-9. PubMed ID: 21768695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer.
    Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P
    Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer.
    Kerin MJ; McAnena OJ; O'Malley VP; Grimes H; Given HF
    Br J Surg; 1989 Aug; 76(8):838-9. PubMed ID: 2765841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is immediate postoperative CA15.3 assay a predictive marker of early postoperative recurrence of carcinoma breast?
    Sarkar DK; Panda N; Biswas S; Saha ML; Majumder A
    J Indian Med Assoc; 2012 Mar; 110(3):146-7. PubMed ID: 23029943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.